Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors
December 23, 2020 07:00 ET
|
Iterum Therapeutics plc
--Dr. Dunne resigns as Chief Scientific Officer-- -- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities-- DUBLIN, Ireland and...
Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
December 21, 2020 17:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority
December 07, 2020 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
November 30, 2020 09:15 ET
|
Iterum Therapeutics plc
--First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved-- --Potential Approval Q3 2021 with Priority Review-- DUBLIN, Ireland and CHICAGO, Nov. 30,...
Iterum Therapeutics Reports Third Quarter 2020 Financial Results
November 16, 2020 06:45 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering
October 23, 2020 00:02 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
October 19, 2020 19:10 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
October 19, 2020 18:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
September 30, 2020 07:00 ET
|
Iterum Therapeutics plc
--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company...
Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
September 08, 2020 16:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...